226 related articles for article (PubMed ID: 35759951)
1. Anakinra and tocilizumab in the chronic phase of febrile infection-related epilepsy syndrome (FIRES): Effectiveness and safety from a case-series.
Aledo-Serrano A; Hariramani R; Gonzalez-Martinez A; Álvarez-Troncoso J; Toledano R; Bayat A; Garcia-Morales I; Becerra JL; Villegas-Martínez I; Beltran-Corbellini A; Gil-Nagel A
Seizure; 2022 Aug; 100():51-55. PubMed ID: 35759951
[TBL] [Abstract][Full Text] [Related]
2. Second-line immunotherapy in new onset refractory status epilepticus.
Hanin A; Muscal E; Hirsch LJ
Epilepsia; 2024 May; 65(5):1203-1223. PubMed ID: 38430119
[TBL] [Abstract][Full Text] [Related]
3. Treatment of new onset refractory status epilepticus/febrile infection-related epilepsy syndrome with tocilizumab in a child and a young adult.
Girardin ML; Flamand T; Roignot O; Abi Warde MT; Mutschler V; Voulleminot P; Guillot M; Dinkelacker V; De Saint-Martin A
Epilepsia; 2023 Jun; 64(6):e87-e92. PubMed ID: 36961094
[TBL] [Abstract][Full Text] [Related]
4. Long-term neuropsychological outcomes in children with febrile infection-related epilepsy syndrome (FIRES) treated with anakinra.
Shrestha A; Wood EL; Berrios-Siervo G; Stredny CM; Boyer K; Vega C; Nangia S; Muscal E; Eschbach K
Front Neurol; 2023; 14():1100551. PubMed ID: 36970506
[TBL] [Abstract][Full Text] [Related]
5. Towards a Treatment for Neuroinflammation in Epilepsy: Interleukin-1 Receptor Antagonist, Anakinra, as a Potential Treatment in Intractable Epilepsy.
Yamanaka G; Ishida Y; Kanou K; Suzuki S; Watanabe Y; Takamatsu T; Morichi S; Go S; Oana S; Yamazaki T; Kawashima H
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208064
[TBL] [Abstract][Full Text] [Related]
6. Febrile infection-related epilepsy syndrome (FIRES) with super-refractory status epilepticus revealing autoimmune encephalitis due to GABA
Caputo D; Iorio R; Vigevano F; Fusco L
Eur J Paediatr Neurol; 2018 Jan; 22(1):182-185. PubMed ID: 29203057
[TBL] [Abstract][Full Text] [Related]
7. Successful Treatment of Pediatric FIRES With Anakinra.
Yang JH; Nataraj S; Sattar S
Pediatr Neurol; 2021 Jan; 114():60-61. PubMed ID: 33227629
[No Abstract] [Full Text] [Related]
8. Interleukin-6 Blockade With Tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES).
Stredny CM; Case S; Sansevere AJ; Son M; Henderson L; Gorman MP
Child Neurol Open; 2020; 7():2329048X20979253. PubMed ID: 33403221
[TBL] [Abstract][Full Text] [Related]
9. Febrile Infection-Related Epilepsy Syndrome Treated Successfully With Anakinra in a 21-Year-Old Woman.
Westbrook C; Subramaniam T; Seagren RM; Tarula E; Co D; Furstenberg-Knauff M; Wallace A; Hsu D; Payne E
WMJ; 2019 Oct; 118(3):135-139. PubMed ID: 31682750
[TBL] [Abstract][Full Text] [Related]
10. Anakinra usage in febrile infection related epilepsy syndrome: an international cohort.
Lai YC; Muscal E; Wells E; Shukla N; Eschbach K; Hyeong Lee K; Kaliakatsos M; Desai N; Wickström R; Viri M; Freri E; Granata T; Nangia S; Dilena R; Brunklaus A; Wainwright MS; Gorman MP; Stredny CM; Asiri A; Hundallah K; Doja A; Payne E; Wirrell E; Koh S; Carpenter JL; Riviello J
Ann Clin Transl Neurol; 2020 Dec; 7(12):2467-2474. PubMed ID: 33506622
[TBL] [Abstract][Full Text] [Related]
11. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
12. Proposal to optimize evaluation and treatment of Febrile infection-related epilepsy syndrome (FIRES): A Report from FIRES workshop.
Koh S; Wirrell E; Vezzani A; Nabbout R; Muscal E; Kaliakatsos M; Wickström R; Riviello JJ; Brunklaus A; Payne E; Valentin A; Wells E; Carpenter JL; Lee K; Lai YC; Eschbach K; Press CA; Gorman M; Stredny CM; Roche W; Mangum T
Epilepsia Open; 2021 Mar; 6(1):62-72. PubMed ID: 33681649
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases.
Gofshteyn JS; Wilfong A; Devinsky O; Bluvstein J; Charuta J; Ciliberto MA; Laux L; Marsh ED
J Child Neurol; 2017 Jan; 32(1):35-40. PubMed ID: 27655472
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol in the acute phase of febrile infection-related epilepsy syndrome (FIRES).
Fetta A; Crotti E; Campostrini E; Bergonzini L; Cesaroni CA; Conti F; Di Pisa V; Gentile V; Mondardini MC; Vezzoli C; Giordano L; Cordelli DM
Epilepsia Open; 2023 Jun; 8(2):685-691. PubMed ID: 37042946
[TBL] [Abstract][Full Text] [Related]
15. Functional deficiency in endogenous interleukin-1 receptor antagonist in patients with febrile infection-related epilepsy syndrome.
Clarkson BDS; LaFrance-Corey RG; Kahoud RJ; Farias-Moeller R; Payne ET; Howe CL
Ann Neurol; 2019 Apr; 85(4):526-537. PubMed ID: 30779222
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of patients with new onset refractory status epilepticus preceded by fever (febrile infection-related epilepsy syndrome) versus without prior fever: An interim analysis.
Jimenez AD; Gopaul M; Asbell H; Aydemir S; Basha MM; Batra A; Damien C; Day GS; Eka O; Eschbach K; Fatima S; Fields MC; Foreman B; Gerard EE; Gofton TE; Haider HA; Hantus ST; Hocker S; Jongeling A; Kalkach Aparicio M; Kandula P; Kang P; Kazazian K; Kellogg MA; Kim M; Lee JW; Marcuse LV; McGraw CM; Mohamed W; Orozco J; Pimentel C; Punia V; Ramirez AM; Steriade C; Struck AF; Taraschenko O; Treister AK; Yoo JY; Zafar S; Zhou DJ; Zutshi D; Gaspard N; Hirsch LJ; Hanin A
Epilepsia; 2024 Jun; 65(6):e87-e96. PubMed ID: 38625055
[TBL] [Abstract][Full Text] [Related]
17. Febrile Infection-Related Epilepsy Syndrome (FIRES): An Overview of Treatment and Recent Patents.
Hon KL; Leung AKC; Torres AR
Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):128-135. PubMed ID: 29745347
[TBL] [Abstract][Full Text] [Related]
18. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES) of unknown aetiology: A comparison of the incomparable?
Nausch E; Schaffeldt L; Tautorat I; Margraf NG; Häusler M; Kluger G; Kellinghaus C; Borzikowsky C; Laufs H; van Baalen A
Seizure; 2022 Mar; 96():18-21. PubMed ID: 35042004
[TBL] [Abstract][Full Text] [Related]
19. Seizures and memory impairment induced by patient-derived anti-N-methyl-D-aspartate receptor antibodies in mice are attenuated by anakinra, an interleukin-1 receptor antagonist.
Taraschenko O; Fox HS; Zekeridou A; Pittock SJ; Eldridge E; Farukhuddin F; Al-Saleem F; Devi Kattala C; Dessain SK; Casale G; Willcockson G; Dingledine R
Epilepsia; 2021 Mar; 62(3):671-682. PubMed ID: 33596332
[TBL] [Abstract][Full Text] [Related]
20. Centromedian thalamic nuclei deep brain stimulation and Anakinra treatment for FIRES - Two different outcomes.
Sa M; Singh R; Pujar S; D'Arco F; Desai N; Eltze C; Hughes E; Al Obaidi M; Eleftheriou D; Tisdall M; Selway R; Cross JH; Kaliakatsos M; Valentin A
Eur J Paediatr Neurol; 2019 Sep; 23(5):749-754. PubMed ID: 31446001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
